Evidence map›Paper›PMID 39459256›Full record

ReviewMolecules (Basel, Switzerland)2024

Recent Progress in Terrestrial Biota Derived Antibacterial Agents for Medical Applications.

Todorka G Vladkova, Younes Smani, Boris L Martinov, Dilyana N Gospodinova

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Todorka G VladkovaDepartment of Polymer Engineering, University of Chemical Technology and Metallurgy, 8 "Kl. Ohridski" Blvd, 1756 Sofia, Bulgaria.ORCID 0000-0003-2789-0157
Younes SmaniAndalusian Center of Developmental Biology, CSIC, Junta de Andalusia, University of Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0001-9302-8384
Boris L MartinovDepartment of Biotechnology, University of Chemical Technology and Metallurgy, 8 "Kl. Ohridski" Blvd, 1756 Sofia, Bulgaria.ORCID 0000-0002-6577-6868
Dilyana N GospodinovaFaculty of Electrical Engineering, Technical University of Sofia, 8 "Kl. Ohridski" Blvd, 1756 Sofia, Bulgaria.ORCID 0000-0002-9524-5478

Funding

Bulgarian Science Fund KP-06-COST/11/07.08.2024.
6 · The paper itself

Abstract

Conventional antibiotic and multidrug treatments are becoming less and less effective and the discovery of new effective and safe antibacterial agents is becoming a global priority. Returning to a natural antibacterial product is a relatively new current trend. Terrestrial biota is a rich source of biologically active substances whose antibacterial potential has not been fully utilized. The aim of this review is to present the current state-of-the-art terrestrial biota-derived antibacterial agents inspired by natural treatments. It summarizes the most important sources and newly identified or modified antibacterial agents and treatments from the last five years. It focuses on the significance of plant- animal- and bacteria-derived biologically active agents as powerful alternatives to antibiotics, as well as the advantages of utilizing natural antibacterial molecules alone or in combination with antibiotics. The main conclusion is that terrestrial biota-derived antibacterial products and substances open a variety of new ways for modern improved therapeutic strategies. New terrestrial sources of known antibacterial agents and new antibacterial agents from terrestrial biota were discovered during the last 5 years, which are under investigation together with some long-ago known but now experiencing their renaissance for the development of new medical treatments. The use of natural antibacterial peptides as well as combinational therapy by commercial antibiotics and natural products is outlined as the most promising method for treating bacterial infections. In vivo testing and clinical trials are necessary to reach clinical application.

Indexed as

Anti-Bacterial AgentsBiological ProductsAnimalsBacteriaBacterial InfectionsBiotaHumansPlantsAnti-Bacterial AgentsBiological Productsantibacterial compoundsantibacterial productsbacteriocinesbiosynthesized nanoparticlescombination treatmentsterrestrial biota

Identifiers

PMID39459256
PMCPMC11510244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.